title: Safety of Ultrasound-Guided Botulinum Toxin Injections for Sialorrhea as Performed by Pediatric Otolaryngologists.
abstract: To evaluate incidence of complications and hospital readmission as a result of ultrasound-guided botulinum toxin injections to manage sialorrhea.
  
  
  
  Case series with chart review.
  
  
  
  Children's Hospital of Wisconsin.
  
  
  
  A case series with chart review was performed of all cases of ultrasound-guided injection of botulinum toxin by pediatric otolaryngologists from March 5, 2010, to September 26, 2014,. Primary outcomes included complications such as dysphagia, aspiration pneumonia, and motor paralysis. Secondary outcomes included hospitalization, intubation, and nasogastric tube placement.
  
  
  
  There were 48 patients, 111 interventions, and 306 intraglandular injections identified. Botulinum toxin type A and type B were utilized in 4 and 107 operative interventions, respectively. Type A was injected into 4 parotid and 4 submandibular glands, utilizing doses of 20 U per parotid and 30 U per submandibular gland. Type B was injected into 98 parotid and 200 submandibular glands, with average dosing of 923 U per parotid and 1170 U per submandibular gland, respectively. There were 2 instances of subjectively worsening of baseline dysphagia that self-resolved. No cases were complicated by aspiration pneumonia or motor paralysis. No patients required hospital readmission, intubation, or nasogastric tube placement.
  
  
  
  Prior published data indicated 16% complication incidence with ultrasound-guided injection of botulinum toxin. Our study found a low complication rate (0.6%) with ultrasound-guided injections of botulinum toxin to manage sialorrhea, without cases of aspiration pneumonia or motor paralysis. Of 306 intraglandular injections, there were 2 cases of worsening baseline subjective dysphagia that self-resolved.
authors.affiliation: Children's Hospital of Wisconsin, Department of Otolaryngology/Medical College of Wisconsin, Children's Hospital Clinics Building, Milwaukee, Wisconsin, USA.
authors.forename: Bahbak
authors.initials: B
authors.lastname: Shariat-Madar
authors.affiliation: Children's Hospital of Wisconsin, Department of Otolaryngology/Medical College of Wisconsin, Children's Hospital Clinics Building, Milwaukee, Wisconsin, USA rchun@mcw.edu.
authors.forename: Robert H
authors.initials: RH
authors.lastname: Chun
authors.affiliation: Children's Hospital of Wisconsin, Department of Otolaryngology/Medical College of Wisconsin, Children's Hospital Clinics Building, Milwaukee, Wisconsin, USA.
authors.forename: Cecille G
authors.initials: CG
authors.lastname: Sulman
authors.affiliation: Children's Hospital of Wisconsin, Department of Otolaryngology/Medical College of Wisconsin, Children's Hospital Clinics Building, Milwaukee, Wisconsin, USA.
authors.forename: Stephen F
authors.initials: SF
authors.lastname: Conley
mesh_terms: D000293:Adolescent; D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D007267:Injections / Q000009:adverse effects / Q000379:methods; D008297:Male; D009465:Neuromuscular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D012798:Sialorrhea / Q000188:drug therapy*; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional; D014922:Wisconsin
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A
keywords: botulinum toxin; cerebral palsy; pediatric otolaryngology; sialorrhea; ultrasound